Vivos Therapeutics, Inc.
corporate_fare Company Profile
Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 48 items for VVOS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 13 rated 8 or above. Recent SEC coverage for VVOS spans DEF 14A, PRER14A, PRE 14A, 8-K.
Recent high-impact activity:
- Vivos Proxy Sets Dec 2 Vote on 1-for-20 to 1-for-40 Reverse Split and Massive Preferred Conversions
- Vivos Proxy Seeks Approval for ~98M Potential New Shares, Reverse Split and Nevada Move
- Vivos Closes No-Cash SOD Deal, Claims $10M+ Equity Boost and Nasdaq Cure
- Vivos Proxy Seeks Approval for 1-for-20 to 1-for-40 Reverse Split and Up to 98M Dilutive Shares
- Vivos Closes SOD Deal, Claims Nasdaq Equity Compliance on $10.4M Booked Gain
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2,358,382 shares in VVOS as of the October 15, 2026 settlement, a 17.7% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 30, 2026, 26.0% of VVOS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for VVOS, detected from its recent SEC filings · based on capital-structure filings through 2026-09-04.
Debt-for-Equity Exchange with Streeterville · Massive Dilution to Existing Holders
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →